top of page
Patrick Cashman.jpg

Former Lundbeck CNS Excecutive, Patrick Cashman, Appointed VP, Neurosciences of Blinktbi, Inc.


Charleston, SC, September 16, 2020 – Blinktbi, Inc., a medical device company exploring non-invasive blink reflex technology for a variety of neurological states and conditions, today announced the appointment of Patrick Cashman as Vice President, Neurosciences, effective immediately.

In a recent press release issued by blinktbi, the company announced newly identified clinical applications for their FDA-cleared blink reflex technology, EyeStat. Blinktbi has foundational research supporting EyeStat’s initial application as a tool to assess for blink reflex abnormalities related to Traumatic Brain Injury (TBI). It has since targeted other promising indications for the device, including diagnosing and monitoring neurological states and conditions. EyeStat also shows promise for evaluating clinical-stage therapeutics being developed to treat these conditions and diseases, including neurological disorders such as Parkinson’s and Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS) and depression.

Patrick Cashman brings to blinktbi the skills, expertise and leadership needed to develop and execute proof of concept in these identified clinical fields. Mr. Cashman is a multicultural executive with nearly 30 years of global experience in the pharmaceutical industry. He has successfully launched new pharmaceutical brands in psychiatry and neurology, including industry leading products in depression, schizophrenia, and Alzheimer’s disease. He has negotiated several product in-license agreements and has led co-commercialization teams with American, European, and Japanese partners.

Prior to blinktbi, Patrick served as President of Lundbeck Canada where his leadership in the area of mental health positioned the company as a true partner in this critical area. Mr. Cashman has been quoted in National Post, Montreal Gazette, and other national publications. He has presented at the Economic Club of Canada, at the Champions of Mental Health Awards, and to members of the Canadian Parliament advocating for reducing stigma and emphasizing the importance of providing adequate resources for the treatment of mental health disorders.

Patrick joins blinktbi following the appointment of Jeffrey Riley as the company’s new Chief Executive Officer. “We are pleased to welcome Patrick to the blinktbi team and expect that his extensive experience in the field of central nervous system disorders will be vital to the company as we develop EyeStat for the potential detection of various diseases,” stated Mr. Riley. “He has effectively managed broad operations, cultivated significant relationships with a number of corporate development leaders in pharma, focused on CNS disorders, and repeatedly structured strategies that enabled some very successful companies in our industry to achieve their clinical and business goals. We look forward to benefiting from Patrick’s knowledge and big pharma experience for our CNS disease programs as well as the other programs in our TBI pipeline,” concluded Mr. Riley.

About blinktbi

Blinktbi, Inc. is a medical device company pioneering blink reflex technology intended to promptly test for and identify a variety of neurological states and conditions. EyeStat is the world’s first FDA-cleared medical device indicated for the assessment of the blink reflex, a component of the startle response. A technological marvel that is part equipment, part software, EyeStat provides objective quantitative data in a matter of minutes. EyeStat captures a subject’s baseline blink reflex and subsequent scans can be used, if warranted, by clinicians to evaluate and assess for abnormalities of the blink reflex. Blinktbi continues to research and apply its technology to several neurological states and conditions, such as traumatic brain injury (TBI), Parkinson’s and Alzheimer’s disease, and ALS, and the effect that each condition has on the blink reflex. The company’s mission is to dramatically improve the detection, differentiation, and management of neurological disease through rapid, noninvasive collection of objective data from the eyes.

bottom of page